YU89103A - Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a - Google Patents
Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-aInfo
- Publication number
- YU89103A YU89103A YU89103A YUP89103A YU89103A YU 89103 A YU89103 A YU 89103A YU 89103 A YU89103 A YU 89103A YU P89103 A YUP89103 A YU P89103A YU 89103 A YU89103 A YU 89103A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- ocd
- obsessive
- related disorders
- compulsive disorder
- gvg
- Prior art date
Links
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 title abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 abstract 2
- 230000006399 behavior Effects 0.000 abstract 1
- 239000003445 gaba agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/853,392 US6462084B1 (en) | 2001-05-14 | 2001-05-14 | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU89103A true YU89103A (sh) | 2006-08-17 |
Family
ID=25315916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU89103A YU89103A (sh) | 2001-05-14 | 2002-05-08 | Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6462084B1 (https=) |
| EP (1) | EP1392273A4 (https=) |
| JP (1) | JP2004533445A (https=) |
| KR (1) | KR20040028758A (https=) |
| CN (1) | CN1509168A (https=) |
| BR (1) | BR0209614A (https=) |
| CA (1) | CA2446641A1 (https=) |
| CZ (1) | CZ20033379A3 (https=) |
| HR (1) | HRP20030894A2 (https=) |
| HU (1) | HUP0400032A3 (https=) |
| IL (1) | IL158761A0 (https=) |
| MX (1) | MXPA03010406A (https=) |
| NO (1) | NO20035037L (https=) |
| NZ (1) | NZ529613A (https=) |
| PL (1) | PL367362A1 (https=) |
| TW (1) | TWI313599B (https=) |
| WO (1) | WO2002092071A1 (https=) |
| YU (1) | YU89103A (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082222A1 (en) | 2000-11-30 | 2002-06-27 | Shapira Nathan Andrew | Treatments for neurogenetic disorders, impulse control disorder, and wound healing |
| AU2003239752A1 (en) * | 2002-06-27 | 2004-01-19 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| US7393537B2 (en) | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
| BRPI0409744A (pt) * | 2003-04-25 | 2006-05-09 | Allergan Inc | emprego de uma neurotoxina de botulinum para aliviar vários distúrbios |
| US20110275664A1 (en) * | 2005-09-26 | 2011-11-10 | The Regents Of The University Of Colorado,A Body Corporate | Method for treating drug and behavioral addictions |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| WO2014197744A1 (en) * | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| CN104306736A (zh) * | 2014-10-31 | 2015-01-28 | 哈尔滨市海江科技开发有限公司 | 一种治疗疑病症的膏药及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4761429A (en) | 1985-07-22 | 1988-08-02 | Kenneth Blum | Enkephalinase and endorphinase inhibitors as anti-craving compositions |
| US5189064A (en) | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
| US4786647A (en) | 1986-06-30 | 1988-11-22 | University Of Florida | Method for eliciting anxiolysis |
| US4980168A (en) | 1989-10-13 | 1990-12-25 | Natrol, Inc. | Dietary supplement for children |
| EP0767174A1 (de) | 1991-11-21 | 1997-04-09 | Ciba-Geigy Ag | Neue Aminoalkanphosphinsäuren und ihre Salze |
| JP3856816B2 (ja) * | 1992-05-20 | 2006-12-13 | ノースウェスターン ユニヴァーシティ | 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体 |
| US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| AP1285A (en) | 1996-06-28 | 2004-06-24 | Ortho Mcneil Pharm Inc | Anticonvulsant sulfamate derivatives useful in treating obesity. |
| US5776956A (en) | 1996-07-30 | 1998-07-07 | Lectec Corporation | Use of cotinine in treating psychiatric disorders |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| KR20010031470A (ko) | 1997-10-28 | 2001-04-16 | 둘락 노먼 씨. | 포유동물의 갈망을 감소시키는 방법 |
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| NZ511173A (en) * | 1998-10-20 | 2003-09-26 | Ortho Mcneil Pharm Inc | Method for treating alcohol dependency, addiction and abuse using anticonvulsant derivatives (such as 2,3:4,5-bis- O-(1-methylethylidene)-beta-D-fructopyranose sulfamate (topiramate)) |
| AU764703B2 (en) | 1999-02-01 | 2003-08-28 | Ortho-Mcneil Pharmaceutical, Inc. | Use of anticonvulsant derivatives for treating bulimia nervosa |
| CN100548290C (zh) | 1999-02-24 | 2009-10-14 | 辛辛那提大学 | 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途 |
| WO2000061140A1 (en) | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
| US20020082222A1 (en) * | 2000-11-30 | 2002-06-27 | Shapira Nathan Andrew | Treatments for neurogenetic disorders, impulse control disorder, and wound healing |
-
2001
- 2001-05-14 US US09/853,392 patent/US6462084B1/en not_active Expired - Fee Related
-
2002
- 2002-05-08 KR KR10-2003-7014792A patent/KR20040028758A/ko not_active Withdrawn
- 2002-05-08 HU HU0400032A patent/HUP0400032A3/hu unknown
- 2002-05-08 HR HR20030894A patent/HRP20030894A2/hr not_active Application Discontinuation
- 2002-05-08 MX MXPA03010406A patent/MXPA03010406A/es active IP Right Grant
- 2002-05-08 YU YU89103A patent/YU89103A/sh unknown
- 2002-05-08 NZ NZ529613A patent/NZ529613A/en unknown
- 2002-05-08 IL IL15876102A patent/IL158761A0/xx unknown
- 2002-05-08 WO PCT/US2002/014344 patent/WO2002092071A1/en not_active Ceased
- 2002-05-08 CN CNA028098269A patent/CN1509168A/zh active Pending
- 2002-05-08 CZ CZ20033379A patent/CZ20033379A3/cs unknown
- 2002-05-08 EP EP02729142A patent/EP1392273A4/en not_active Withdrawn
- 2002-05-08 BR BR0209614-5A patent/BR0209614A/pt not_active IP Right Cessation
- 2002-05-08 JP JP2002588988A patent/JP2004533445A/ja active Pending
- 2002-05-08 CA CA002446641A patent/CA2446641A1/en not_active Abandoned
- 2002-05-08 PL PL02367362A patent/PL367362A1/xx not_active Application Discontinuation
- 2002-05-13 TW TW091109922A patent/TWI313599B/zh not_active IP Right Cessation
- 2002-06-20 US US10/175,576 patent/US20020169103A1/en not_active Abandoned
-
2003
- 2003-11-13 NO NO20035037A patent/NO20035037L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ529613A (en) | 2006-09-29 |
| NO20035037D0 (no) | 2003-11-13 |
| CN1509168A (zh) | 2004-06-30 |
| HUP0400032A3 (en) | 2012-09-28 |
| CZ20033379A3 (cs) | 2004-12-15 |
| TWI313599B (en) | 2009-08-21 |
| IL158761A0 (en) | 2004-05-12 |
| HUP0400032A2 (hu) | 2004-04-28 |
| US6462084B1 (en) | 2002-10-08 |
| MXPA03010406A (es) | 2004-05-05 |
| WO2002092071A1 (en) | 2002-11-21 |
| KR20040028758A (ko) | 2004-04-03 |
| EP1392273A4 (en) | 2004-11-24 |
| EP1392273A1 (en) | 2004-03-03 |
| US20020169103A1 (en) | 2002-11-14 |
| HRP20030894A2 (en) | 2004-06-30 |
| BR0209614A (pt) | 2004-12-07 |
| NO20035037L (no) | 2004-01-07 |
| CA2446641A1 (en) | 2002-11-21 |
| JP2004533445A (ja) | 2004-11-04 |
| PL367362A1 (en) | 2005-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04006280A (es) | Compuestos espiroazaciclicos como moduladores de receptor de monoamina. | |
| MY142777A (en) | Substituted indole-o-glucosides | |
| UA87991C2 (en) | Substituted indole-o-glucosides | |
| SG149063A1 (en) | Use of modified cyclosporins for the treatment of hcv disorders | |
| WO2003101397A3 (en) | Tetravalent dengue vaccines | |
| MY180762A (en) | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators. | |
| YU89503A (sh) | Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti | |
| IL142900A0 (en) | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer | |
| TW200518769A (en) | Use of calcitonin in osteoarthritis | |
| YU89103A (sh) | Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a | |
| GB0111186D0 (en) | Novel compounds | |
| WO2003088748A8 (en) | Use of heme oxygenase-1 and products of heme degradation | |
| AU1171102A (en) | Uridine therapy for patients with elevated purine levels | |
| IL161501A0 (en) | Methods of preventing and treating flavivirus infection in animals | |
| TW200716088A (en) | Formulations and methods for treating amyloidosis | |
| MXPA03011270A (es) | Uso de antagonistas rank para tratar cancer. | |
| ATE383874T1 (de) | Perylenequinonen zur anwendung als sonosensitizer | |
| UA85187C2 (en) | 2-aminobenzoyl derivatives | |
| GB9924941D0 (en) | Treatment of dyskinesia | |
| EP1430025A4 (en) | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING BACTERIAL INFECTIONS | |
| MXPA04000272A (es) | Derivados de 4-aminociclohexanol sustituidos. | |
| MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. | |
| MXPA04000008A (es) | Carbamatos de 2-heterociclic-1,2-etanodioles. | |
| AU2001276323A1 (en) | Use of n-oleoylethanolamine for treating psoriasis | |
| NO20004363L (no) | Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme |